Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 1
1995 1
1996 1
1997 3
1999 1
2000 1
2001 1
2002 1
2003 3
2006 1
2012 1
2013 2
2014 1
2015 1
2016 4
2017 4
2018 14
2019 18
2020 12
2021 29
2022 16
2023 13
2024 24
2025 35
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

203 results

Results by year

Filters applied: . Clear all
Page 1
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, MaCurdy TE, Kelman J, Dooling K. Izurieta HS, et al. Clin Infect Dis. 2021 Sep 15;73(6):941-948. doi: 10.1093/cid/ciab125. Clin Infect Dis. 2021. PMID: 33580242 Free article.
BACKGROUND: Shingrix (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed as 2 doses given 2-6 months apart among adults aged 50 years. ...Herpes zoster was identified using a medical office visit d …
BACKGROUND: Shingrix (recombinant zoster vaccine) was licensed to prevent herpes zoster, dispensed …
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.
Heineman TC, Cunningham A, Levin M. Heineman TC, et al. Curr Opin Immunol. 2019 Aug;59:42-48. doi: 10.1016/j.coi.2019.02.009. Epub 2019 Apr 17. Curr Opin Immunol. 2019. PMID: 31003070 Review.
Herpes zoster is common in older and immune suppressed persons due to diminished VZV-specific cellular immunity. A recombinant herpes zoster vaccine (RZV) consisting of a single VZV glycoprotein and an adjuvant system stimulates robust an …
Herpes zoster is common in older and immune suppressed persons due to diminished VZV-specific cellular immunity. A recombin …
Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.
James SF, Chahine EB, Sucher AJ, Hanna C. James SF, et al. Ann Pharmacother. 2018 Jul;52(7):673-680. doi: 10.1177/1060028018758431. Epub 2018 Feb 18. Ann Pharmacother. 2018. PMID: 29457489 Review.
OBJECTIVES: To review the immunogenicity, efficacy, and safety of the herpes zoster subunit vaccine (HZ/su) for use in adult patients for the prevention of shingles. ...DATA SYNTHESIS: HZ/su is a new adjuvanted recombinant vaccine approved by th …
OBJECTIVES: To review the immunogenicity, efficacy, and safety of the herpes zoster subunit vaccine (HZ/su) for use in …
Recombinant Zoster Vaccine (Shingrix( )): A Review in Herpes Zoster.
Syed YY. Syed YY. Drugs Aging. 2018 Dec;35(12):1031-1040. doi: 10.1007/s40266-018-0603-x. Drugs Aging. 2018. PMID: 30370455 Review.
Shingrix( ) is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01(B) adjuvant system. The subunit vaccine is approved for the prevention of herpes …
Shingrix( ) is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus …
Recombinant zoster vaccine (Shingrix( )): a new option for the prevention of herpes zoster and postherpetic neuralgia.
Singh G, Song S, Choi E, Lee PB, Nahm FS. Singh G, et al. Korean J Pain. 2020 Jul 1;33(3):201-207. doi: 10.3344/kjp.2020.33.3.201. Korean J Pain. 2020. PMID: 32606264 Free PMC article. Review.
The live zoster vaccine (LZV, Zostavax( )) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine ( …
The live zoster vaccine (LZV, Zostavax( )) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be …
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group. Cunningham AL, et al. N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. N Engl J Med. 2016. PMID: 27626517 Free article. Clinical Trial.
BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system w …
BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (H …
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged 19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Anderson TC, et al. MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):80-84. doi: 10.15585/mmwr.mm7103a2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35051134 Free PMC article.
Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit vaccine containing recombinant glycoprotein E in combination with adjuvant (AS01(B)) that was licensed in the United States for pre …
Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit va …
Risk of Guillain-Barre Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
Goud R, Lufkin B, Duffy J, Whitaker B, Wong HL, Liao J, Lo AC, Parulekar S, Agger P, Anderson SA, Wernecke M, MaCurdy TE, Weintraub E, Kelman JA, Forshee RA. Goud R, et al. JAMA Intern Med. 2021 Dec 1;181(12):1623-1630. doi: 10.1001/jamainternmed.2021.6227. JAMA Intern Med. 2021. PMID: 34724025 Free PMC article.
This study assesses the risk of Guillain-Barre syndrome after administration of recombinant zoster vaccine (RZV or Shingrix), which is administered in 2 doses 2 to 6 months apart. OBJECTIVE: Use Medicare claims data to evaluate risk of developing Guill …
This study assesses the risk of Guillain-Barre syndrome after administration of recombinant zoster vaccine (RZV or S …
Herpes Zoster Vaccines.
Harbecke R, Cohen JI, Oxman MN. Harbecke R, et al. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S429-S442. doi: 10.1093/infdis/jiab387. J Infect Dis. 2021. PMID: 34590136 Free PMC article.
The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoster vaccines, a live-attenuated varicella-zoster virus (VZV) vaccine (zoster vaccine live [ZVL]; ZOSTAVAX [Mer …
The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoste …
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Dagnew AF, et al. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. Lancet Infect Dis. 2019. PMID: 31399377 Clinical Trial.
BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. ...INTERPRETATION: The immunocompromised adult population with haemato …
BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in olde …
203 results